On Wednesday, shares jumped 78% to 1.43, likely on the FDA news. Never Miss The News Again Do you want real-time, actionable news … When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Addex Therapeutics Ltd (ADXN) is up 140% at $25.34 in pre-market trading Thursday, on news that its partner Janssen Pharmaceuticals Inc., a Johnson & Johnson (JNJ) company, has received FDA clearance to begin a Phase 2a proof of concept study with JNJ-40411813 (ADX71149), in patients with epilepsy. Feb 17, 2021. Especially critical now with anaphylactic shock often following Covid vaccination. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. I support this company, help me do the same! Until then it's just going to hover around at its current price/dip a bit further. More Info About Adamis Pharmaceuticals Corporation (ADMP) Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, engages in developing and commercializing products in the therapeutic areas of allergy and respiratory disease. ADMP closed Wednesday's trading at $0.69, down 9.47%. Tecentriq is already indicated for use in the treatment of urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, and small cell lung cancer. SAN DIEGO , Jan. 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) in collaboration with the Human Immune Monitoring Center at Stanford University have conducted a study to investigate the effects of Tempol on immune cells from COVID-19 patients. In The Money: The Rise of Vaccines And Interest Rates, #TradeTalks: Inflation, rates and what it’s going to take to get the market to the next level, Do Not Sell My Personal Information (CA Residents Only). January 29, 2021 - 9:00 am. FPRX closed Wednesday's trading at $5.23, up 18.33%. Eton remains confident that it can successfully complete the requested human factors validation study, however, the study is unlikely to be completed by the due date. KPTI closed Wednesday's trading at $16.32, down 0.12%. In after-hours, the stock was down 8.13% at $19.90. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Create your Watchlist to save your favorite quotes on Nasdaq.com. Adamis Pharmaceuticals (NASDAQ: ADMP) shot up over 27% in premarket trading after announcing the submission of an Investigational New Drug to the FDA for the use of Tempol. The drug … FDA news releases, media contacts, speeches, meetings and workshops, and other ways that FDA engages with the public. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The decision date on ET-105 is due on March 17, 2020. SAN DIEGO , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") announced today that the U.S. Food and Drug Administration (“FDA”) has completed the safety review of the Company’s Investigational New Drug (“IND”) application and has concluded that. Directors, Customized Adamis Pharmaceuticals Corp. (ADMP) expects to resubmit ZIMHI New Drug Application early in the second quarter of 2020. Heron resubmitted an NDA to the FDA for HTX-011 in September 2019 and was initially assigned a decision date of March 26, 2020. SAN DIEGO , Jan. 21, 2021 (GLOBE NEWSWIRE) -- Adamis   Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its SYMJEPI ® (epinephrine) Injection products are now available to members of the Walgreens Prescription Savings Club program, for a discounted price of $99.99 for a two-pack, the. The point is that as evident by FDA approval of SYMJEPI .3mg ADMP solved the volume delivery and patient usability issues satisfactorily. After two CRL's SYMJEPI received FDA approval in June of 2017. XPOVIO received accelerated FDA approval in July 2019 in combination with dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma. SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, announced today that it intends to offer to sell shares of its common stock in an underwritten … The addressable market opportunity for … The FDA is expected to make a decision on approval by May 2021. These symbols will be available throughout the site during your session. products in the therapeutic areas of respiratory disease and allergy. HRTX closed Wednesday's trading at $21.66, up 2.48%. The FDA had turned down HTX-011 on April 30, 2019, due to issues related to chemistry, manufacturing and controls and non-clinical information. Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a specialty Adamis Pharmaceuticals Corp. (ADMP) Adamis Pharma's ZIMHI Injection, proposed for the reversal of opioid overdose, awaits the FDA decision, due on November 15. Adamis (ADMP) submits an investigational new drug (IND) ... Veklury (remdesivir), was approved by the FDA in October 2020 to treat COVID-19. Original Poster 5 days ago. Medications, Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19, Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate, Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock, Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock, Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock, Adamis Pharmaceuticals and Human Immune Monitoring Center at Stanford University Announce Preliminary Tempol Data in Cells from COVID-19 Patients, Adamis Pharmaceuticals Provides Update On Its US Compounding Business, SYMJEPI Products Now Available in the Walgreens Prescription Savings Club, with the Lowest Prices for Epinephrine Products, Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19, Adamis Pharmaceuticals Describes Planned Response to ZIMHI Complete Response Letter, Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding ZIMHI, Adamis Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update, Adamis Pharmaceuticals Schedules Third Quarter 2020 Results Conference Call and Business Update, Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders, Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders and Proposals, Adamis Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update, Adamis Pharmaceuticals Announces Pre-IND Feedback from FDA Enabling Advancement of Tempol, a Novel Anti-Inflammatory and Anti-Oxidant Drug for the Treatment of COVID-19, Adamis Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement, Adamis Pharmaceuticals Provides Update on SYMJEPI Products, Adamis Pharmaceuticals Announces Publication of Pharmacokinetic model suggesting that higher doses of naloxone are needed for successful resuscitation due to fentanyl overdose, Adamis Pharmaceuticals Announces License to Commercialize Tempol, a Novel Investigational Anti-inflammatory and Antioxidant Drug for the Treatment of Respiratory Diseases Including COVID-19, Adamis Pharmaceuticals Announces Publication of Pharmacokinetic study comparing ZIMHI to current 2 mg intramuscular dose of naloxone, Board The Chief Executive Officer of the company, Dr. Dennis J. Carlo, stated that the issues raised by the FDA can be managed, and Adamis will fully cooperate with the regulatory agency. This time, the Company has sought approval of Tecentriq as a first-line (initial) monotherapy for people with advanced non-squamous and squamous non-small cell lung cancer without EGFR or ALK mutations with high PD-L1 expression (TC3/IC3 wild-type [WT]), as determined by PD-L1 biomarker testing. Copy and paste multiple symbols separated by spaces. Naloxone has been used as the standard treatment for opioid overdose for more than 45 years, and the currently approved dose is only 2 mg. ADMP 01-20 investorplace.com - Adamis Pharma (NASDAQ:ADMP) stock is taking off on Wednesday following news of a possible treatment for the novel coronavirus. SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Company") announced today that the U.S. Food and Drug Administration ("FDA") has completed the safety review of the Company's Investigational New Drug ("IND") application and has concluded that Adamis may proceed with the proposed clinical investigation of Tempol for the treatment of COVID-19. SAN DIEGO , Dec. 01, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) today announced a planned response to a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA), regarding its New Drug Application (NDA) for Adamis’ ZIMHI ™ high dose naloxone. (RTTNews) - Today's Daily Dose brings you news about Adamis Pharma's upcoming regulatory catalyst, the delay in FDA decision related to Eton Pharma's drug candidate, the global license agreement between Five Prime and Seattle Genetics, and Karyopharm's date with FDA. RHHBY.OB closed Wednesday's trading at $44.73, up 1.44%. SAN DIEGO , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Adamis   Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that after the close of business and the U.S. markets on November 13 th , it received a Complete Response Letter (CRL) from the U.S. SAN DIEGO , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Adamis   Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2020 and provided a business update. As part of the deal, Five Prime has granted Seattle Genetics an exclusive worldwide license to a family of monoclonal antibodies that are directed to a single target and Seattle Genetics will be responsible for research, development, manufacturing, and commercialization of antibody-drug conjugate, or ADC, products based on these antibodies. The clearance to proceed follows the submission of an IND application to FDA … Type a symbol or company name. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) announced that the FDA has approved Epinephrine pre-filled syringe for the emergency treatment of allergic reactions (Type I) including anaphylaxis.The company had previously received two Complete Response Letters (CRLs) from the FDA rejecting previous submissions so Thursday’s news will no doubt be a relief to both the company and … The Company was issued a Complete Response Letter by the FDA for ZIMHI last November. Price Action: ADMP stock is … ZIMHI is a high-dose naloxone injection product candidate intended for the treatment of opioid overdose. Adamis Pharmaceuticals has been expecting an approval letter from the FDA regarding its naloxone product candidate, ZIMHI. level 2. Reply. News Release Adamis Pharmaceuticals Receives FDA Approval for Its Lower Dose Symjepi Product SAN DIEGO , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved Adamis’ lower dose version (0.15mg) of Symjepi ™ for the emergency treatment of allergic … Corporate News, FDA, Management Comments. Karyopharm Therapeutics Inc.'s (KPTI) supplemental New Drug Application seeking accelerated approval for oral XPOVIO tablets has been accepted for priority review by the FDA, with a decision date set for June 23, 2020. Kudos to Adamis Pharmaceutical (ADMP) for providing epi pens for half the price of Mylan, who screwed millions patients who needed it to save their lives. It took over a year for the company to close a U.S. commercial partnership deal with … Which Assets Will Gain Most From Stimulus? SAN DIEGO , Sept. 17, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, SAN DIEGO , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the results of its reconvened 2020 annual meeting of stockholders which was initially held August 20, 2020 , and was adjourned until September 3, 2020 . ADMP stock plunged by as much as 50% at 0.63 after the news broke. ET-105 is proposed as an adjunct therapy for partial seizures, primary generalized tonic-clonic seizures, and generalized seizures of Lennox-Gastaut syndrome in patients two years of age and older. HTX-011 is proposed for the management of postoperative pain. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals, SAN DIEGO , Aug. 14, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that in response to Adamis’ Pre-Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA), the FDA has provided detailed comments regarding the, SAN DIEGO , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that it has received a letter from the NASDAQ Listing Qualifications Staff (“Nasdaq”) notifying the company that as a result of the closing bid price of the company’s common stock having, SAN DIEGO , July 01, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that, on July 1, 2020 , USWM, LLC (“USWM” or “US WorldMeds”) began promoting Adamis’ SYMJEPI ® (epinephrine) Injection 0.3mg and SYMJEPI ® (epinephrine) Injection 0.15mg products through, SAN DIEGO , June 18, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the publication of an article entitled “Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu, SAN DIEGO , June 15, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today a license  to commercialize Tempol, a novel patented investigational drug for the treatment of Coronavirus (COVID-19). Roche's (RHHBY.OB) supplemental Biologics License Application for Tecentriq as a first-line treatment for certain people with advanced non-small cell lung cancer has been granted priority review by the FDA, with a decision date set for June 19, 2020. Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms.